An international team of surgeons and scientists has, for the first time, validated safe surgical access to the central core of the human cochlea in a study funded by Rinri Therapeutics, a biotech company developing regenerative cell therapies for sensorineural hearing loss (SNHL).
Key highlights:
- A team of surgeons and scientists from the UK, Sweden and Canada, funded by Rinri Therapeutics, has confirmed secure surgical access to the central core of the human cochlea.
- The research is critical to the first in-human trials of new cell, gene and drug therapies for the inner ear, and will assist with treatment for improving hearing loss and deafness over the long-term.
The team from Guy’s and St Thomas’ NHS Foundation Trust in London, and the universities of Uppsala (Sweden), Sheffield, Nottingham, and Western University in Canada, has proven and confirmed a secure clinical pathway to the inner ear, which will enable the application of a range of regenerative therapies to restore hearing.
The human cochlea lies in the base of the skull, encased by the hardest bone in the human body. This has hampered the progress of discovering new treatments for hearing loss. Using a detailed representation of the microanatomy of the peripheral auditory neural structure, surgeons have now been able to reach the human cochlea safely with a routine surgical approach.
Marcelo Rivolta, professor of Sensory Stem Cell Biology at the University of Sheffield and Founder of Rinri Therapeutics, said: “Until now this region of the inner ear has been inaccessible in humans. This means that the pioneering advanced therapies to repair the auditory nerve using stem cells, which have already proved successful in animal models, have been hampered by limited anatomical knowledge and the lack of a safe access to Rosenthal’s canal - the compartment that houses the auditory neurons within the central core of the cochlea.
“We believe these findings will have immediate impact on both our understanding of the microstructure of the inner ear and the first in-human trials of new cell, gene and drug therapies to improve hearing loss and deafness.”
Dr. Simon Chandler, CEO of Rinri Therapeutics, said: “People with severe hearing loss often suffer an enormous negative impact on their quality of life, withdrawing from their communities because their disability inhibits interactions with others. This research now paves the way for the successful delivery of our regenerative cell therapy for hearing loss, that will bring significant positive impacts to healthcare systems and economies across the globe.”
Gerry O’Donoghue, professor of Otology and Neurotology at the University of Nottingham, and clinical advisor to Rinri Therapeutics: “The inaccessibility of the human cochlea has hampered the progress of curative treatments for SNHL to date. These findings however will enable the safe delivery of regenerative therapeutics to their target structures within the relatively impenetrable human cochlea, de-risking future clinical interventions and paving the way for clinical trials.”
Professor Sumit Agrawal, from Western University in Canada, said: “We are delighted that our data was able to contribute to such a vital piece of research, which will enable significant advancements in the clinical trials and treatment of sensorineural hearing loss.”
The study, published in the latest issue of Scientific Reports, was funded by a grant from Rinri Therapeutics in collaboration with the Swedish Hearing Research Foundation. Scientists at the University of Nottingham led the investigation with support from the universities of Sheffield and Uppsala in Sweden, who conducted all the modelling and imaging for the project. Surgical validation was led by surgeons at Guy’s and St. Thomas’ Hospital in London. The project relied heavily on scan data made available by Western University in Canada.